Literature DB >> 29173081

Varicella Virus Vaccination in the United States.

Jana Shaw1, Anne A Gershon2.   

Abstract

Varicella zoster virus (VZV) is the cause of chickenpox (varicella) and shingles (zoster), and was once responsible for over 4 million infections in the United States annually. The development of a live attenuated VZV vaccine was initially viewed with extreme skepticism. Nonetheless, a VZV vaccine was developed in the 1970s by Takahashi and his colleagues in Japan and was eventually licensed in the US. It is now known to be one of the safest and most effective vaccines available and is administered worldwide. Here are described important factors that contributed to the successful research and licensure of the highly successful VZV vaccine.

Entities:  

Keywords:  latent virus; varicella vaccine; varicella zoster virus

Mesh:

Substances:

Year:  2017        PMID: 29173081      PMCID: PMC5863082          DOI: 10.1089/vim.2017.0136

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  60 in total

1.  A full-genome phylogenetic analysis of varicella-zoster virus reveals a novel origin of replication-based genotyping scheme and evidence of recombination between major circulating clades.

Authors:  Geoffrey A Peters; Shaun D Tyler; Charles Grose; Alberto Severini; Michael J Gray; Chris Upton; Graham A Tipples
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Application of a live varicella vaccine in children with acute leukemia or other malignant diseases.

Authors:  T Izawa; T Ihara; A Hattori; T Iwasa; H Kamiya; M Sakurai; M Takahashi
Journal:  Pediatrics       Date:  1977-12       Impact factor: 7.124

3.  Varicell vaccine at the crossroads.

Authors:  C H Kempe
Journal:  Pediatrics       Date:  1977-12       Impact factor: 7.124

4.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence.

Authors:  V Williams; A Gershon; P A Brunell
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

5.  Prevention of varicella by zoster immune globulin.

Authors:  P A Brunell; A Ross; L H Miller; B Kuo
Journal:  N Engl J Med       Date:  1969-05-29       Impact factor: 91.245

Review 6.  The varicella-zoster virus genome.

Authors:  Jeffrey I Cohen
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

7.  Use of Saliva to Identify Varicella Zoster Virus Infection of the Gut.

Authors:  Anne A Gershon; Jason Chen; Michael D Gershon
Journal:  Clin Infect Dis       Date:  2015-04-16       Impact factor: 9.079

8.  Effectiveness over time of varicella vaccine.

Authors:  Marietta Vázquez; Philip S LaRussa; Anne A Gershon; Linda M Niccolai; Catherine E Muehlenbein; Sharon P Steinberg; Eugene D Shapiro
Journal:  JAMA       Date:  2004-02-18       Impact factor: 56.272

Review 9.  Safety of vaccines used for routine immunization of U.S. children: a systematic review.

Authors:  Margaret A Maglione; Lopamudra Das; Laura Raaen; Alexandria Smith; Ramya Chari; Sydne Newberry; Roberta Shanman; Tanja Perry; Matthew Bidwell Goetz; Courtney Gidengil
Journal:  Pediatrics       Date:  2014-07-01       Impact factor: 7.124

10.  Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox.

Authors:  M Brisson; N J Gay; W J Edmunds; N J Andrews
Journal:  Vaccine       Date:  2002-06-07       Impact factor: 3.641

View more
  3 in total

Review 1.  Assessing and restoring adaptive immunity to HSV, VZV, and HHV-6 in solid organ and hematopoietic cell transplant recipients.

Authors:  Madeleine R Heldman; Kaja M Aagaard; Joshua A Hill
Journal:  Clin Microbiol Infect       Date:  2022-02-10       Impact factor: 13.310

Review 2.  Aging and Options to Halt Declining Immunity to Virus Infections.

Authors:  Miguel Ángel Palacios-Pedrero; Albert D M E Osterhaus; Tanja Becker; Husni Elbahesh; Guus F Rimmelzwaan; Giulietta Saletti
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

Review 3.  Clinical Features of Varicella-Zoster Virus Infection.

Authors:  Peter G E Kennedy; Anne A Gershon
Journal:  Viruses       Date:  2018-11-02       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.